Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Ishida A et al. | Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation--a prospective analysis. | 1998 | Transfusion | pmid:9738624 |
Allen C et al. | Polycaprolactone-b-poly(ethylene oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents FK506 and L-685,818. | 1998 Sep-Oct | Bioconjug. Chem. | pmid:9736490 |
Hodak SP et al. | QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. | 1998 | Transplantation | pmid:9734501 |
Wiesner RH | A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. | 1998 | Transplantation | pmid:9734494 |
Sussman MA et al. | Prevention of cardiac hypertrophy in mice by calcineurin inhibition. | 1998 | Science | pmid:9733519 |
Cogill JL et al. | Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. | 1998 | Clin. Chem. | pmid:9732981 |
Kawahara K et al. | Tracheal transplantation for carinal reconstruction in dogs. | 1998 | J. Thorac. Cardiovasc. Surg. | pmid:9731780 |
Meiser BM et al. | Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. | 1998 | J. Heart Lung Transplant. | pmid:9730427 |
Reichart B et al. | European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results--European Tacrolimus Multicenter Heart Study Group. | 1998 | J. Heart Lung Transplant. | pmid:9730426 |
Horning NR et al. | Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. | 1998 | J. Heart Lung Transplant. | pmid:9730424 |
Winter C et al. | MAP kinase phosphatase 1 is expressed and enhanced by FK506 in surviving mamillary, but not degenerating nigral neurons following axotomy. | 1998 | Brain Res. | pmid:9729383 |
Gammie JS et al. | A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment. | 1998 | Exp. Hematol. | pmid:9728927 |
Snyder SH et al. | Immunophilins in the nervous system. | 1998 | Neuron | pmid:9728910 |
Garcia-Cozar FJ et al. | Two-site interaction of nuclear factor of activated T cells with activated calcineurin. | 1998 | J. Biol. Chem. | pmid:9727000 |
Reddy SS and Holley JL | Nocardiosis in a recently transplanted renal patient. | 1998 | Clin. Nephrol. | pmid:9725785 |
Thielke J et al. | Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome. | 1998 | Liver Transpl Surg | pmid:9724482 |
Herzberg GZ et al. | Usefulness of tacrolimus versus cyclosporine after pediatric heart transplantation. | 1998 | Am. J. Cardiol. | pmid:9723652 |
Miyata Y et al. | Development of xenogeneic microchimerism correlated with graft outcome in hamster-to-rat heart xenotransplantation. | 1998 | Transplant. Proc. | pmid:9723548 |
Hanack U et al. | Is there a different impact of cyclosporine versus tacrolimus on delayed graft function after kidney transplantation? | 1998 | Transplant. Proc. | pmid:9723477 |
Fritsche L et al. | Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function. | 1998 | Transplant. Proc. | pmid:9723451 |
Pirsch JD | Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic. | 1998 | Transplant. Proc. | pmid:9723448 |
Xu M et al. | FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. | 1998 | Transplant. Proc. | pmid:9723447 |
Yonan NA et al. | Tracheal allograft transplantation in rats: the role of immunosuppressive agents in development of obliterative airway disease. | 1998 | Transplant. Proc. | pmid:9723443 |
Perego C et al. | Study of the immunosuppressive effect of SMS 201-995 and its synergic action with FK 506. | 1998 | Transplant. Proc. | pmid:9723434 |
Jonas S et al. | Five-year follow-up of tacrolimus as primary immunosuppressant after liver transplantation. | 1998 | Transplant. Proc. | pmid:9723433 |
Busuttil RW and Holt CD | Tacrolimus is superior to cyclosporine in liver transplantation. | 1998 | Transplant. Proc. | pmid:9723432 |
Vanrenterghem Y | Tacrolimus (FK 506) in kidney transplantation. | 1998 | Transplant. Proc. | pmid:9723431 |
Halloran PF et al. | Calcineurin and the biological effect of cyclosporine and tacrolimus. | 1998 | Transplant. Proc. | pmid:9723430 |
Otto C et al. | Selective immunosuppression with FK 506, anti-IL-2R, and anti-ICAM-1 monoclonal antibodies: contrasting effects after liver and small bowel transplantation in rats. | 1998 | Transplant. Proc. | pmid:9723426 |
Kohnle M et al. | Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia. | 1998 | Transplant. Proc. | pmid:9723413 |
Atillasoy E et al. | Cholesterol levels long-term after liver transplant. | 1998 | Transplant. Proc. | pmid:9723387 |
Varghese Z et al. | Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. | 1998 | Transplant. Proc. | pmid:9723384 |
Donadio C et al. | Tubular damage and impairment of renal function in transplanted kidneys. | 1998 | Transplant. Proc. | pmid:9723381 |
Burrows L et al. | Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients. | 1998 | Transplant. Proc. | pmid:9723378 |
Yoshimura R et al. | Hepatocyte growth factor: a sensitive indicator for CsA-induced nephropathy. | 1998 | Transplant. Proc. | pmid:9723373 |
Curtis JJ | Posttransplant hypertension. | 1998 | Transplant. Proc. | pmid:9723370 |
Falkenstein K and Dunn S | Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient. | 1998 | Transplant. Proc. | pmid:9723354 |
Ettenger RB | New immunosuppressive agents in pediatric renal transplantation. | 1998 | Transplant. Proc. | pmid:9723350 |
Berweck S et al. | Clinical use of the euglycemic hyperinsulinemic clamp for diagnosis of tacrolimus-induced insulin resistance after combined pancreas-kidney transplantation. | 1998 | Transplant. Proc. | pmid:9723345 |
Behr TM et al. | Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A. | 1998 | Transplant. Proc. | pmid:9723333 |
Lang M et al. | Combined liver-kidney transplantation: long-term follow-up in 18 patients. | 1998 | Transplant. Proc. | pmid:9723313 |
Lagget M et al. | Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients. | 1998 | Transplant. Proc. | pmid:9723312 |
Gridelli B et al. | Frequency of switch from cyclosporine to FK 506 before and after Neoral use in pediatric liver transplantation. | 1998 | Transplant. Proc. | pmid:9723311 |
Alberti D et al. | Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation. | 1998 | Transplant. Proc. | pmid:9723310 |
Reggiani P et al. | Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression. | 1998 | Transplant. Proc. | pmid:9723308 |
Rayes N et al. | Distribution of lymphocyte subtypes in liver transplant recipients with viral reinfection or de novo malignancy. | 1998 | Transplant. Proc. | pmid:9723303 |
Peeters P et al. | Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: results from an International Randomized Controlled Trial. Milton Study Group. | 1998 | Transplant. Proc. | pmid:9723301 |
Van Buren D et al. | Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients. | 1998 | Transplant. Proc. | pmid:9723299 |
McMaster P et al. | Liver transplantation: changing goals in immunosuppression. | 1998 | Transplant. Proc. | pmid:9723295 |
Levy GA | Neoral is superior to FK 506 in liver transplantation. | 1998 | Transplant. Proc. | pmid:9723293 |